GoodRx (NASDAQ:GDRX) Reaches New 12-Month Low After Analyst Downgrade

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) hit a new 52-week low during mid-day trading on Wednesday after Citigroup lowered their price target on the stock from $10.00 to $7.00. Citigroup currently has a buy rating on the stock. GoodRx traded as low as $4.61 and last traded at $4.63, with a volume of 871841 shares. The stock had previously closed at $4.70.

GDRX has been the topic of a number of other reports. Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective on the stock in a report on Friday, August 9th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price target on shares of GoodRx in a report on Friday, August 16th. UBS Group lowered their price target on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a report on Friday, August 9th. Finally, Barclays lowered their price target on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, GoodRx presently has a consensus rating of “Moderate Buy” and an average target price of $8.86.

Insider Transactions at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.17% of the company’s stock.

Hedge Funds Weigh In On GoodRx

A number of hedge funds have recently made changes to their positions in GDRX. Beacon Capital Management LLC purchased a new position in GoodRx in the 1st quarter valued at approximately $28,000. nVerses Capital LLC purchased a new stake in GoodRx in the third quarter valued at $33,000. Plato Investment Management Ltd purchased a new stake in GoodRx in the second quarter valued at $43,000. Dark Forest Capital Management LP purchased a new stake in GoodRx in the second quarter valued at $86,000. Finally, EntryPoint Capital LLC lifted its position in GoodRx by 165.2% in the first quarter. EntryPoint Capital LLC now owns 18,538 shares of the company’s stock valued at $132,000 after acquiring an additional 11,548 shares during the last quarter. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Trading Down 0.9 %

The stock has a market capitalization of $1.77 billion, a PE ratio of -153.67, a PEG ratio of 3.24 and a beta of 1.39. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The business’s 50-day moving average is $6.76 and its two-hundred day moving average is $7.48.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.